JP2000516957A - 置換されている1,2,3,4―テトラヒドロ―2―ジベンゾフランアミン類および2―アミノシクロヘプタ[b]ベンゾフラン類 - Google Patents
置換されている1,2,3,4―テトラヒドロ―2―ジベンゾフランアミン類および2―アミノシクロヘプタ[b]ベンゾフラン類Info
- Publication number
- JP2000516957A JP2000516957A JP10511794A JP51179498A JP2000516957A JP 2000516957 A JP2000516957 A JP 2000516957A JP 10511794 A JP10511794 A JP 10511794A JP 51179498 A JP51179498 A JP 51179498A JP 2000516957 A JP2000516957 A JP 2000516957A
- Authority
- JP
- Japan
- Prior art keywords
- dimethyl
- tetrahydro
- mmol
- phenyl
- carboxamide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- GJUCAWYIAWECBW-UHFFFAOYSA-N 1h-cyclohepta[b][1]benzofuran-2-amine Chemical class O1C2=CC=CC=CC2=C2C1=CC=C(N)C2 GJUCAWYIAWECBW-UHFFFAOYSA-N 0.000 title abstract description 5
- JCFPKIOSTZEMSZ-UHFFFAOYSA-N 1,2,3,4-tetrahydrodibenzofuran-2-amine Chemical class O1C2=CC=CC=C2C2=C1CCC(N)C2 JCFPKIOSTZEMSZ-UHFFFAOYSA-N 0.000 title description 3
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 claims abstract description 50
- 150000001875 compounds Chemical class 0.000 claims description 166
- -1 α-methyl-4-nitrobenzyl Chemical group 0.000 claims description 125
- 238000000034 method Methods 0.000 claims description 58
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 47
- 150000003839 salts Chemical class 0.000 claims description 23
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 14
- 125000000623 heterocyclic group Chemical group 0.000 claims description 13
- 239000001257 hydrogen Substances 0.000 claims description 11
- 229910052739 hydrogen Inorganic materials 0.000 claims description 11
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 8
- 125000001624 naphthyl group Chemical group 0.000 claims description 8
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 8
- 241000124008 Mammalia Species 0.000 claims description 7
- 230000004913 activation Effects 0.000 claims description 7
- 229910052740 iodine Inorganic materials 0.000 claims description 3
- 125000005301 thienylmethyl group Chemical group [H]C1=C([H])C([H])=C(S1)C([H])([H])* 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 2
- 239000008024 pharmaceutical diluent Substances 0.000 claims description 2
- 125000001475 halogen functional group Chemical group 0.000 claims 6
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 4
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 3
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 2
- 239000000556 agonist Substances 0.000 abstract description 6
- JDNMMYSBXKIHEO-UHFFFAOYSA-N 1,2,3,4-tetrahydrodibenzofuran-1,2-diamine Chemical class NC1C(CCC=2OC3=C(C21)C=CC=C3)N JDNMMYSBXKIHEO-UHFFFAOYSA-N 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 description 142
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 75
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 54
- 239000000203 mixture Substances 0.000 description 54
- 230000002829 reductive effect Effects 0.000 description 49
- 239000011541 reaction mixture Substances 0.000 description 46
- 239000000243 solution Substances 0.000 description 39
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 36
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 35
- 238000006243 chemical reaction Methods 0.000 description 33
- 239000007787 solid Substances 0.000 description 33
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 30
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 27
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 27
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 26
- 238000004364 calculation method Methods 0.000 description 26
- 150000002923 oximes Chemical class 0.000 description 26
- 239000002253 acid Substances 0.000 description 25
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 24
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 24
- 239000000047 product Substances 0.000 description 24
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 22
- 239000002585 base Substances 0.000 description 22
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 22
- 102000005962 receptors Human genes 0.000 description 22
- 108020003175 receptors Proteins 0.000 description 22
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 21
- 230000015572 biosynthetic process Effects 0.000 description 21
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 20
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 18
- 239000002904 solvent Substances 0.000 description 18
- 206010015866 Extravasation Diseases 0.000 description 16
- 230000036251 extravasation Effects 0.000 description 16
- 125000005843 halogen group Chemical group 0.000 description 16
- 238000003786 synthesis reaction Methods 0.000 description 16
- 208000019695 Migraine disease Diseases 0.000 description 15
- 230000027455 binding Effects 0.000 description 15
- 235000019441 ethanol Nutrition 0.000 description 15
- 206010027599 migraine Diseases 0.000 description 15
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 15
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 14
- 239000012141 concentrate Substances 0.000 description 14
- 229910052938 sodium sulfate Inorganic materials 0.000 description 14
- 235000011152 sodium sulphate Nutrition 0.000 description 14
- 235000008504 concentrate Nutrition 0.000 description 13
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 13
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 13
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 12
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 12
- 150000001412 amines Chemical class 0.000 description 12
- 125000005605 benzo group Chemical group 0.000 description 12
- 235000019253 formic acid Nutrition 0.000 description 12
- 238000003756 stirring Methods 0.000 description 12
- 239000003814 drug Substances 0.000 description 11
- 238000002844 melting Methods 0.000 description 11
- 230000008018 melting Effects 0.000 description 11
- 229910000027 potassium carbonate Inorganic materials 0.000 description 11
- 239000011780 sodium chloride Substances 0.000 description 11
- 125000001424 substituent group Chemical group 0.000 description 11
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 10
- 125000001309 chloro group Chemical group Cl* 0.000 description 10
- 238000004587 chromatography analysis Methods 0.000 description 10
- JHIVVAPYMSGYDF-UHFFFAOYSA-N cyclohexanone Chemical compound O=C1CCCCC1 JHIVVAPYMSGYDF-UHFFFAOYSA-N 0.000 description 10
- SQDFHQJTAWCFIB-UHFFFAOYSA-N n-methylidenehydroxylamine Chemical compound ON=C SQDFHQJTAWCFIB-UHFFFAOYSA-N 0.000 description 10
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 10
- 108090000623 proteins and genes Proteins 0.000 description 10
- 238000010992 reflux Methods 0.000 description 10
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 9
- 125000000217 alkyl group Chemical group 0.000 description 9
- 239000000284 extract Substances 0.000 description 9
- 238000004519 manufacturing process Methods 0.000 description 9
- 239000012074 organic phase Substances 0.000 description 9
- 102000004169 proteins and genes Human genes 0.000 description 9
- 229920006395 saturated elastomer Polymers 0.000 description 9
- 241001269524 Dura Species 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 8
- 125000004093 cyano group Chemical group *C#N 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 239000003921 oil Substances 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 7
- 208000002193 Pain Diseases 0.000 description 7
- 239000002168 alkylating agent Substances 0.000 description 7
- 229940100198 alkylating agent Drugs 0.000 description 7
- 239000007810 chemical reaction solvent Substances 0.000 description 7
- 238000002425 crystallisation Methods 0.000 description 7
- 230000008025 crystallization Effects 0.000 description 7
- 238000000605 extraction Methods 0.000 description 7
- 125000001153 fluoro group Chemical group F* 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 239000000758 substrate Substances 0.000 description 7
- 210000000427 trigeminal ganglion Anatomy 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 6
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 6
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
- 239000000908 ammonium hydroxide Substances 0.000 description 6
- 239000008346 aqueous phase Substances 0.000 description 6
- 125000001246 bromo group Chemical group Br* 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 6
- 239000004615 ingredient Substances 0.000 description 6
- ORARBYAEFARIRC-UHFFFAOYSA-N n-[4-(dimethylamino)cyclohexylidene]hydroxylamine Chemical compound CN(C)C1CCC(=NO)CC1 ORARBYAEFARIRC-UHFFFAOYSA-N 0.000 description 6
- 230000009467 reduction Effects 0.000 description 6
- 238000007363 ring formation reaction Methods 0.000 description 6
- 229940076279 serotonin Drugs 0.000 description 6
- 230000000638 stimulation Effects 0.000 description 6
- KQKPFRSPSRPDEB-UHFFFAOYSA-N sumatriptan Chemical compound CNS(=O)(=O)CC1=CC=C2NC=C(CCN(C)C)C2=C1 KQKPFRSPSRPDEB-UHFFFAOYSA-N 0.000 description 6
- 102000040125 5-hydroxytryptamine receptor family Human genes 0.000 description 5
- 108091032151 5-hydroxytryptamine receptor family Proteins 0.000 description 5
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 5
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
- 150000007513 acids Chemical class 0.000 description 5
- 125000003545 alkoxy group Chemical group 0.000 description 5
- 229910052799 carbon Inorganic materials 0.000 description 5
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 5
- 239000003054 catalyst Substances 0.000 description 5
- 239000012954 diazonium Substances 0.000 description 5
- 150000001989 diazonium salts Chemical class 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 5
- 238000001914 filtration Methods 0.000 description 5
- 238000010438 heat treatment Methods 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 5
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 5
- 239000008194 pharmaceutical composition Substances 0.000 description 5
- 229910052697 platinum Inorganic materials 0.000 description 5
- NTTOTNSKUYCDAV-UHFFFAOYSA-N potassium hydride Chemical compound [KH] NTTOTNSKUYCDAV-UHFFFAOYSA-N 0.000 description 5
- 229910000105 potassium hydride Inorganic materials 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 239000000741 silica gel Substances 0.000 description 5
- 229910002027 silica gel Inorganic materials 0.000 description 5
- 238000010898 silica gel chromatography Methods 0.000 description 5
- 239000011734 sodium Substances 0.000 description 5
- 229910000029 sodium carbonate Inorganic materials 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 4
- XEZNGIUYQVAUSS-UHFFFAOYSA-N 18-crown-6 Chemical compound C1COCCOCCOCCOCCOCCO1 XEZNGIUYQVAUSS-UHFFFAOYSA-N 0.000 description 4
- SMNDYUVBFMFKNZ-UHFFFAOYSA-N 2-furoic acid Chemical compound OC(=O)C1=CC=CO1 SMNDYUVBFMFKNZ-UHFFFAOYSA-N 0.000 description 4
- ZSLUVFAKFWKJRC-IGMARMGPSA-N 232Th Chemical compound [232Th] ZSLUVFAKFWKJRC-IGMARMGPSA-N 0.000 description 4
- IHCCAYCGZOLTEU-UHFFFAOYSA-N 3-furoic acid Chemical compound OC(=O)C=1C=COC=1 IHCCAYCGZOLTEU-UHFFFAOYSA-N 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- 241000700198 Cavia Species 0.000 description 4
- OHCQJHSOBUTRHG-KGGHGJDLSA-N FORSKOLIN Chemical compound O=C([C@@]12O)C[C@](C)(C=C)O[C@]1(C)[C@@H](OC(=O)C)[C@@H](O)[C@@H]1[C@]2(C)[C@@H](O)CCC1(C)C OHCQJHSOBUTRHG-KGGHGJDLSA-N 0.000 description 4
- 101000941893 Felis catus Leucine-rich repeat and calponin homology domain-containing protein 1 Proteins 0.000 description 4
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical class OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 4
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- 229910052776 Thorium Inorganic materials 0.000 description 4
- 239000007983 Tris buffer Substances 0.000 description 4
- 230000029936 alkylation Effects 0.000 description 4
- 238000005804 alkylation reaction Methods 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 150000001502 aryl halides Chemical class 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 230000008499 blood brain barrier function Effects 0.000 description 4
- 210000001218 blood-brain barrier Anatomy 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 230000008878 coupling Effects 0.000 description 4
- 238000010168 coupling process Methods 0.000 description 4
- 238000005859 coupling reaction Methods 0.000 description 4
- 230000005595 deprotonation Effects 0.000 description 4
- 238000010537 deprotonation reaction Methods 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 239000007903 gelatin capsule Substances 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 238000006722 reduction reaction Methods 0.000 description 4
- 239000011347 resin Substances 0.000 description 4
- 229920005989 resin Polymers 0.000 description 4
- 229910052708 sodium Inorganic materials 0.000 description 4
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 229960003708 sumatriptan Drugs 0.000 description 4
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 4
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 4
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 4
- 238000010626 work up procedure Methods 0.000 description 4
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 3
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 3
- LMBFUMXVHAJSNJ-UHFFFAOYSA-N 4-(dimethylamino)cyclohexan-1-one Chemical compound CN(C)C1CCC(=O)CC1 LMBFUMXVHAJSNJ-UHFFFAOYSA-N 0.000 description 3
- OTCYOBLTAQTFPW-UHFFFAOYSA-N 4-aminocyclohexan-1-one Chemical compound NC1CCC(=O)CC1 OTCYOBLTAQTFPW-UHFFFAOYSA-N 0.000 description 3
- CZKLEJHVLCMVQR-UHFFFAOYSA-N 4-fluorobenzoyl chloride Chemical compound FC1=CC=C(C(Cl)=O)C=C1 CZKLEJHVLCMVQR-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 3
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 206010047139 Vasoconstriction Diseases 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 150000001450 anions Chemical class 0.000 description 3
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 3
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 238000009903 catalytic hydrogenation reaction Methods 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000003776 cleavage reaction Methods 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- DCZFGQYXRKMVFG-UHFFFAOYSA-N cyclohexane-1,4-dione Chemical compound O=C1CCC(=O)CC1 DCZFGQYXRKMVFG-UHFFFAOYSA-N 0.000 description 3
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 3
- 238000001704 evaporation Methods 0.000 description 3
- 230000008020 evaporation Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000006260 foam Substances 0.000 description 3
- 239000012458 free base Substances 0.000 description 3
- 238000005984 hydrogenation reaction Methods 0.000 description 3
- 239000000543 intermediate Substances 0.000 description 3
- 238000002386 leaching Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 239000002480 mineral oil Substances 0.000 description 3
- 235000010446 mineral oil Nutrition 0.000 description 3
- PYLWMHQQBFSUBP-UHFFFAOYSA-N monofluorobenzene Chemical compound FC1=CC=CC=C1 PYLWMHQQBFSUBP-UHFFFAOYSA-N 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 150000003141 primary amines Chemical class 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
- RVQZKNOMKUSGCI-UHFFFAOYSA-N pyridine-4-carbonyl chloride Chemical compound ClC(=O)C1=CC=NC=C1 RVQZKNOMKUSGCI-UHFFFAOYSA-N 0.000 description 3
- 239000002287 radioligand Substances 0.000 description 3
- 230000007017 scission Effects 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 3
- 230000025033 vasoconstriction Effects 0.000 description 3
- 229920002554 vinyl polymer Polymers 0.000 description 3
- ZBNZAJFNDPPMDT-UHFFFAOYSA-N 1h-imidazole-5-carboxamide Chemical compound NC(=O)C1=CNC=N1 ZBNZAJFNDPPMDT-UHFFFAOYSA-N 0.000 description 2
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- LSBDFXRDZJMBSC-UHFFFAOYSA-N 2-phenylacetamide Chemical compound NC(=O)CC1=CC=CC=C1 LSBDFXRDZJMBSC-UHFFFAOYSA-N 0.000 description 2
- CUYKNJBYIJFRCU-UHFFFAOYSA-N 3-aminopyridine Chemical compound NC1=CC=CN=C1 CUYKNJBYIJFRCU-UHFFFAOYSA-N 0.000 description 2
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 2
- 125000004217 4-methoxybenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1OC([H])([H])[H])C([H])([H])* 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
- WVUYHQGFRBLVRT-UHFFFAOYSA-N 8-(dimethylamino)-6,7,8,9-tetrahydrodibenzofuran-2-ol Chemical compound O1C2=CC=C(O)C=C2C2=C1CCC(N(C)C)C2 WVUYHQGFRBLVRT-UHFFFAOYSA-N 0.000 description 2
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 2
- GWJNOHFTYDILNE-UHFFFAOYSA-N C(C1=CC=CC=C1)(=O)O.N1=C(C=NC=C1)C(=O)N Chemical compound C(C1=CC=CC=C1)(=O)O.N1=C(C=NC=C1)C(=O)N GWJNOHFTYDILNE-UHFFFAOYSA-N 0.000 description 2
- SUZLHDUTVMZSEV-UHFFFAOYSA-N Deoxycoleonol Natural products C12C(=O)CC(C)(C=C)OC2(C)C(OC(=O)C)C(O)C2C1(C)C(O)CCC2(C)C SUZLHDUTVMZSEV-UHFFFAOYSA-N 0.000 description 2
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 2
- QIAFMBKCNZACKA-UHFFFAOYSA-N N-benzoylglycine Chemical compound OC(=O)CNC(=O)C1=CC=CC=C1 QIAFMBKCNZACKA-UHFFFAOYSA-N 0.000 description 2
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- DPWPWRLQFGFJFI-UHFFFAOYSA-N Pargyline Chemical compound C#CCN(C)CC1=CC=CC=C1 DPWPWRLQFGFJFI-UHFFFAOYSA-N 0.000 description 2
- YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000010933 acylation Effects 0.000 description 2
- 238000005917 acylation reaction Methods 0.000 description 2
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000011260 aqueous acid Substances 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- 125000005161 aryl oxy carbonyl group Chemical group 0.000 description 2
- PASDCCFISLVPSO-UHFFFAOYSA-N benzoyl chloride Chemical compound ClC(=O)C1=CC=CC=C1 PASDCCFISLVPSO-UHFFFAOYSA-N 0.000 description 2
- WTEOIRVLGSZEPR-UHFFFAOYSA-N boron trifluoride Chemical compound FB(F)F WTEOIRVLGSZEPR-UHFFFAOYSA-N 0.000 description 2
- WOBLPDAWNVAVAS-UHFFFAOYSA-N butyl carboxy carbonate Chemical compound CCCCOC(=O)OC(O)=O WOBLPDAWNVAVAS-UHFFFAOYSA-N 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 150000001805 chlorine compounds Chemical class 0.000 description 2
- NEHMKBQYUWJMIP-UHFFFAOYSA-N chloromethane Chemical compound ClC NEHMKBQYUWJMIP-UHFFFAOYSA-N 0.000 description 2
- OHCQJHSOBUTRHG-UHFFFAOYSA-N colforsin Natural products OC12C(=O)CC(C)(C=C)OC1(C)C(OC(=O)C)C(O)C1C2(C)C(O)CCC1(C)C OHCQJHSOBUTRHG-UHFFFAOYSA-N 0.000 description 2
- 150000003983 crown ethers Chemical class 0.000 description 2
- 125000000753 cycloalkyl group Chemical group 0.000 description 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- CGZZMOTZOONQIA-UHFFFAOYSA-N cycloheptanone Chemical compound O=C1CCCCCC1 CGZZMOTZOONQIA-UHFFFAOYSA-N 0.000 description 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 2
- 239000002027 dichloromethane extract Substances 0.000 description 2
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 150000002081 enamines Chemical class 0.000 description 2
- 150000002148 esters Chemical group 0.000 description 2
- YVPJCJLMRRTDMQ-UHFFFAOYSA-N ethyl diazoacetate Chemical compound CCOC(=O)C=[N+]=[N-] YVPJCJLMRRTDMQ-UHFFFAOYSA-N 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- QEWYKACRFQMRMB-UHFFFAOYSA-N fluoroacetic acid Chemical compound OC(=O)CF QEWYKACRFQMRMB-UHFFFAOYSA-N 0.000 description 2
- 238000001640 fractional crystallisation Methods 0.000 description 2
- BTUIFMCWPFMNRG-UHFFFAOYSA-N furan-3-carbonyl chloride Chemical compound ClC(=O)C=1C=COC=1 BTUIFMCWPFMNRG-UHFFFAOYSA-N 0.000 description 2
- 238000007429 general method Methods 0.000 description 2
- 150000002367 halogens Chemical group 0.000 description 2
- 210000003128 head Anatomy 0.000 description 2
- 150000002431 hydrogen Chemical class 0.000 description 2
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 2
- 150000002466 imines Chemical class 0.000 description 2
- 239000011630 iodine Substances 0.000 description 2
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 2
- 239000012948 isocyanate Substances 0.000 description 2
- 150000002513 isocyanates Chemical class 0.000 description 2
- VFQXVTODMYMSMJ-UHFFFAOYSA-N isonicotinamide Chemical compound NC(=O)C1=CC=NC=C1 VFQXVTODMYMSMJ-UHFFFAOYSA-N 0.000 description 2
- 229910052744 lithium Inorganic materials 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- QPJVMBTYPHYUOC-UHFFFAOYSA-N methyl benzoate Chemical compound COC(=O)C1=CC=CC=C1 QPJVMBTYPHYUOC-UHFFFAOYSA-N 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- LQFFSGFXNACILA-UHFFFAOYSA-N n-[8-(dimethylamino)-6,7,8,9-tetrahydrodibenzofuran-2-yl]-4-fluorobenzamide Chemical compound C1=C2C=3CC(N(C)C)CCC=3OC2=CC=C1NC(=O)C1=CC=C(F)C=C1 LQFFSGFXNACILA-UHFFFAOYSA-N 0.000 description 2
- 229910000510 noble metal Inorganic materials 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 235000006408 oxalic acid Nutrition 0.000 description 2
- 125000004430 oxygen atom Chemical group O* 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N p-toluenesulfonic acid Substances CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- 229960001779 pargyline Drugs 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- YPFDHNVEDLHUCE-UHFFFAOYSA-N propane-1,3-diol Chemical compound OCCCO YPFDHNVEDLHUCE-UHFFFAOYSA-N 0.000 description 2
- 125000006239 protecting group Chemical group 0.000 description 2
- RJLCIACWXJHILW-UHFFFAOYSA-N pyridine-4-carboxamide;dihydrochloride Chemical compound Cl.Cl.NC(=O)C1=CC=NC=C1 RJLCIACWXJHILW-UHFFFAOYSA-N 0.000 description 2
- LEHBURLTIWGHEM-UHFFFAOYSA-N pyridinium chlorochromate Chemical compound [O-][Cr](Cl)(=O)=O.C1=CC=[NH+]C=C1 LEHBURLTIWGHEM-UHFFFAOYSA-N 0.000 description 2
- 238000003127 radioimmunoassay Methods 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- 238000005932 reductive alkylation reaction Methods 0.000 description 2
- 150000003335 secondary amines Chemical class 0.000 description 2
- 239000003762 serotonin receptor affecting agent Substances 0.000 description 2
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 2
- 229910000104 sodium hydride Inorganic materials 0.000 description 2
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Inorganic materials [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 2
- 235000010288 sodium nitrite Nutrition 0.000 description 2
- 238000003797 solvolysis reaction Methods 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 229940124530 sulfonamide Drugs 0.000 description 2
- 150000003456 sulfonamides Chemical group 0.000 description 2
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 2
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 2
- 229960000658 sumatriptan succinate Drugs 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000005062 synaptic transmission Effects 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 125000001544 thienyl group Chemical group 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 239000003039 volatile agent Substances 0.000 description 2
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 1
- BVXAYWYLMBLZPD-OCCSQVGLSA-N (2s)-8-nitro-n-[(1r)-1-(4-nitrophenyl)ethyl]-1,2,3,4-tetrahydrodibenzofuran-2-amine Chemical compound C1([C@H](N[C@@H]2CC=3C4=CC(=CC=C4OC=3CC2)[N+]([O-])=O)C)=CC=C([N+]([O-])=O)C=C1 BVXAYWYLMBLZPD-OCCSQVGLSA-N 0.000 description 1
- VQTTTYQUDXOEDD-WLHGVMLRSA-N (e)-but-2-enedioic acid;n-[2-(dimethylamino)-1h-cyclohepta[b][1]benzofuran-9-yl]-1h-1,2,4-triazole-5-carboxamide Chemical compound OC(=O)\C=C\C(O)=O.C=1C2=C3CC(N(C)C)=CC=C3OC2=CC=CC=1NC(=O)C1=NC=NN1 VQTTTYQUDXOEDD-WLHGVMLRSA-N 0.000 description 1
- LKYNGTHMKCTTQC-UHFFFAOYSA-N 1,2-oxazole-3-carboxamide Chemical compound NC(=O)C=1C=CON=1 LKYNGTHMKCTTQC-UHFFFAOYSA-N 0.000 description 1
- KPZGRMZPZLOPBS-UHFFFAOYSA-N 1,3-dichloro-2,2-bis(chloromethyl)propane Chemical compound ClCC(CCl)(CCl)CCl KPZGRMZPZLOPBS-UHFFFAOYSA-N 0.000 description 1
- VAELWSLNTRVXQS-UHFFFAOYSA-N 1,3-oxazole-4-carboxamide Chemical compound NC(=O)C1=COC=N1 VAELWSLNTRVXQS-UHFFFAOYSA-N 0.000 description 1
- HFZZTHJMXZSGFP-UHFFFAOYSA-N 1-benzofuran-2-amine Chemical group C1=CC=C2OC(N)=CC2=C1 HFZZTHJMXZSGFP-UHFFFAOYSA-N 0.000 description 1
- MZAUQUVYPHLLDF-UHFFFAOYSA-N 1-benzofuran-4-carboxamide Chemical compound NC(=O)C1=CC=CC2=C1C=CO2 MZAUQUVYPHLLDF-UHFFFAOYSA-N 0.000 description 1
- PWKNBLFSJAVFAB-UHFFFAOYSA-N 1-fluoro-2-nitrobenzene Chemical compound [O-][N+](=O)C1=CC=CC=C1F PWKNBLFSJAVFAB-UHFFFAOYSA-N 0.000 description 1
- WFQDTOYDVUWQMS-UHFFFAOYSA-N 1-fluoro-4-nitrobenzene Chemical compound [O-][N+](=O)C1=CC=C(F)C=C1 WFQDTOYDVUWQMS-UHFFFAOYSA-N 0.000 description 1
- GQMYQEAXTITUAE-UHFFFAOYSA-N 1H-indole-5-carboxamide Chemical compound NC(=O)C1=CC=C2NC=CC2=C1 GQMYQEAXTITUAE-UHFFFAOYSA-N 0.000 description 1
- RLOQBKJCOAXOLR-UHFFFAOYSA-N 1h-pyrrole-2-carboxamide Chemical compound NC(=O)C1=CC=CN1 RLOQBKJCOAXOLR-UHFFFAOYSA-N 0.000 description 1
- PVCQAOQLECLXAF-UHFFFAOYSA-N 2,3-dihydroxybutanedioic acid;n-[2-(dimethylamino)-1h-cyclohepta[b][1]benzofuran-9-yl]-5-fluoro-1-benzofuran-3-carboxamide Chemical compound OC(=O)C(O)C(O)C(O)=O.O1C2=CC=CC(NC(=O)C=3C4=CC(F)=CC=C4OC=3)=CC2=C2C1=CC=C(N(C)C)C2 PVCQAOQLECLXAF-UHFFFAOYSA-N 0.000 description 1
- HCSBTDBGTNZOAB-UHFFFAOYSA-N 2,3-dinitrobenzoic acid Chemical compound OC(=O)C1=CC=CC([N+]([O-])=O)=C1[N+]([O-])=O HCSBTDBGTNZOAB-UHFFFAOYSA-N 0.000 description 1
- OBTZDIRUQWFRFZ-UHFFFAOYSA-N 2-(5-methylfuran-2-yl)-n-(4-methylphenyl)quinoline-4-carboxamide Chemical compound O1C(C)=CC=C1C1=CC(C(=O)NC=2C=CC(C)=CC=2)=C(C=CC=C2)C2=N1 OBTZDIRUQWFRFZ-UHFFFAOYSA-N 0.000 description 1
- BFELUTJUZYXOCS-UHFFFAOYSA-N 2-(dimethylamino)-1h-cyclohepta[b][1]benzofuran-9-ol Chemical compound O1C2=CC=CC(O)=CC2=C2C1=CC=C(N(C)C)C2 BFELUTJUZYXOCS-UHFFFAOYSA-N 0.000 description 1
- WITPWJNAVYJIOP-UHFFFAOYSA-N 2-(methanesulfonamido)butanedioic acid Chemical compound CS(=O)(=O)NC(C(O)=O)CC(O)=O WITPWJNAVYJIOP-UHFFFAOYSA-N 0.000 description 1
- XZXYQEHISUMZAT-UHFFFAOYSA-N 2-[(2-hydroxy-5-methylphenyl)methyl]-4-methylphenol Chemical compound CC1=CC=C(O)C(CC=2C(=CC=C(C)C=2)O)=C1 XZXYQEHISUMZAT-UHFFFAOYSA-N 0.000 description 1
- KMLPEYHLAKSCGX-UHFFFAOYSA-N 2-aminocyclohexan-1-one Chemical compound NC1CCCCC1=O KMLPEYHLAKSCGX-UHFFFAOYSA-N 0.000 description 1
- 125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 description 1
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- KBKJQORWMDEPAL-UHFFFAOYSA-N 2-n,2-n-diethyl-1,2,3,4-tetrahydrodibenzofuran-2,8-diamine;dihydrochloride Chemical compound Cl.Cl.O1C2=CC=C(N)C=C2C2=C1CCC(N(CC)CC)C2 KBKJQORWMDEPAL-UHFFFAOYSA-N 0.000 description 1
- UFTQWASGOXZAEQ-UHFFFAOYSA-N 2-n,2-n-dimethyl-1,2,3,4-tetrahydrodibenzofuran-2,8-diamine;dihydrochloride Chemical compound Cl.Cl.O1C2=CC=C(N)C=C2C2=C1CCC(N(C)C)C2 UFTQWASGOXZAEQ-UHFFFAOYSA-N 0.000 description 1
- JXHGGGPYYGBQDI-UHFFFAOYSA-N 2-n,2-n-dimethyl-1h-cyclohepta[b][1]benzofuran-2,9-diamine Chemical class O1C2=CC=CC(N)=CC2=C2C1=CC=C(N(C)C)C2 JXHGGGPYYGBQDI-UHFFFAOYSA-N 0.000 description 1
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- JSOKVKDUOOIHST-UHFFFAOYSA-N 3-chloro-n-[2-(dimethylamino)-1h-cyclohepta[b][1]benzofuran-9-yl]benzenesulfonamide Chemical compound C=1C2=C3CC(N(C)C)=CC=C3OC2=CC=CC=1NS(=O)(=O)C1=CC=CC(Cl)=C1 JSOKVKDUOOIHST-UHFFFAOYSA-N 0.000 description 1
- 125000003682 3-furyl group Chemical group O1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- WHBMMWSBFZVSSR-UHFFFAOYSA-N 3-hydroxybutyric acid Chemical compound CC(O)CC(O)=O WHBMMWSBFZVSSR-UHFFFAOYSA-N 0.000 description 1
- 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- VLBFVLHJVBXWIM-UHFFFAOYSA-N 4-(dimethylamino)cyclohexan-1-one;hydrochloride Chemical compound Cl.CN(C)C1CCC(=O)CC1 VLBFVLHJVBXWIM-UHFFFAOYSA-N 0.000 description 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- MADJXSYPYYHDPT-UHFFFAOYSA-N 4-aminocycloheptan-1-one Chemical compound NC1CCCC(=O)CC1 MADJXSYPYYHDPT-UHFFFAOYSA-N 0.000 description 1
- IMLXLGZJLAOKJN-UHFFFAOYSA-N 4-aminocyclohexan-1-ol Chemical compound NC1CCC(O)CC1 IMLXLGZJLAOKJN-UHFFFAOYSA-N 0.000 description 1
- NUKYPUAOHBNCPY-UHFFFAOYSA-N 4-aminopyridine Chemical compound NC1=CC=NC=C1 NUKYPUAOHBNCPY-UHFFFAOYSA-N 0.000 description 1
- PXACTUVBBMDKRW-UHFFFAOYSA-N 4-bromobenzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=C(Br)C=C1 PXACTUVBBMDKRW-UHFFFAOYSA-N 0.000 description 1
- XRHGYUZYPHTUJZ-UHFFFAOYSA-M 4-chlorobenzoate Chemical compound [O-]C(=O)C1=CC=C(Cl)C=C1 XRHGYUZYPHTUJZ-UHFFFAOYSA-M 0.000 description 1
- 125000004801 4-cyanophenyl group Chemical group [H]C1=C([H])C(C#N)=C([H])C([H])=C1* 0.000 description 1
- RRUNUZOMEZXGPY-UHFFFAOYSA-N 4-ethoxyisoindole-1,3-dione Chemical compound CCOC1=CC=CC2=C1C(=O)NC2=O RRUNUZOMEZXGPY-UHFFFAOYSA-N 0.000 description 1
- WURMPFYVFDHATI-UHFFFAOYSA-N 4-fluoro-n,n-dimethylbenzenesulfonamide Chemical compound CN(C)S(=O)(=O)C1=CC=C(F)C=C1 WURMPFYVFDHATI-UHFFFAOYSA-N 0.000 description 1
- KRZCOLNOCZKSDF-UHFFFAOYSA-N 4-fluoroaniline Chemical compound NC1=CC=C(F)C=C1 KRZCOLNOCZKSDF-UHFFFAOYSA-N 0.000 description 1
- AEKVBBNGWBBYLL-UHFFFAOYSA-N 4-fluorobenzonitrile Chemical compound FC1=CC=C(C#N)C=C1 AEKVBBNGWBBYLL-UHFFFAOYSA-N 0.000 description 1
- RVWDWHQBBITUDU-UHFFFAOYSA-N 4-methoxy-n-[2-(propan-2-ylamino)-1h-cyclohepta[b][1]benzofuran-9-yl]-1h-indole-2-carboxamide Chemical compound C=1C=2C(OC)=CC=CC=2NC=1C(=O)NC(C=CC=C1O2)=CC1=C1C2=CC=C(NC(C)C)C1 RVWDWHQBBITUDU-UHFFFAOYSA-N 0.000 description 1
- GMCKRXYRIXYNBI-UHFFFAOYSA-N 4-methylbenzenesulfonic acid;n-[8-(2-methylpropylamino)-6,7,8,9-tetrahydrodibenzofuran-2-yl]quinoline-4-carboxamide Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1.C1=CC=C2C(C(=O)NC3=CC=C4OC=5CCC(CC=5C4=C3)NCC(C)C)=CC=NC2=C1 GMCKRXYRIXYNBI-UHFFFAOYSA-N 0.000 description 1
- OBKXEAXTFZPCHS-UHFFFAOYSA-N 4-phenylbutyric acid Chemical compound OC(=O)CCCC1=CC=CC=C1 OBKXEAXTFZPCHS-UHFFFAOYSA-N 0.000 description 1
- ZQUXUQXIXIVEQA-UHFFFAOYSA-N 6-(dimethylamino)-6,7,8,9-tetrahydro-5h-carbazol-3-ol Chemical compound N1C2=CC=C(O)C=C2C2=C1CCC(N(C)C)C2 ZQUXUQXIXIVEQA-UHFFFAOYSA-N 0.000 description 1
- BWRTZCLWLBXVEM-UHFFFAOYSA-N 8-(dimethylamino)-6,7,8,9-tetrahydrodibenzofuran-2-carbonitrile Chemical compound O1C2=CC=C(C#N)C=C2C2=C1CCC(N(C)C)C2 BWRTZCLWLBXVEM-UHFFFAOYSA-N 0.000 description 1
- NTHPWSUJZJEEKG-UHFFFAOYSA-N 8-(dimethylamino)-6,7,8,9-tetrahydrodibenzofuran-2-carboxylic acid Chemical compound O1C2=CC=C(C(O)=O)C=C2C2=C1CCC(N(C)C)C2 NTHPWSUJZJEEKG-UHFFFAOYSA-N 0.000 description 1
- PECTVLIVSZNEMY-UHFFFAOYSA-N 8-(dimethylamino)-n-(4-fluorophenyl)-6,7,8,9-tetrahydrodibenzofuran-2-carboxamide Chemical compound C1=C2C=3CC(N(C)C)CCC=3OC2=CC=C1C(=O)NC1=CC=C(F)C=C1 PECTVLIVSZNEMY-UHFFFAOYSA-N 0.000 description 1
- POAGWOKHVZTKKK-UHFFFAOYSA-N 8-(dimethylamino)-n-ethyl-6,7,8,9-tetrahydrodibenzofuran-2-carboxamide Chemical compound C1CC(N(C)C)CC2=C1OC1=CC=C(C(=O)NCC)C=C12 POAGWOKHVZTKKK-UHFFFAOYSA-N 0.000 description 1
- JMHOWMVLWZACFE-UHFFFAOYSA-N 8-(dimethylamino)-n-methyl-6,7,8,9-tetrahydrodibenzofuran-2-carboxamide Chemical compound C1CC(N(C)C)CC2=C1OC1=CC=C(C(=O)NC)C=C12 JMHOWMVLWZACFE-UHFFFAOYSA-N 0.000 description 1
- IDXQGNLNRBHUNL-UHFFFAOYSA-N 8-(dimethylamino)-n-pyridin-3-yl-6,7,8,9-tetrahydrodibenzofuran-2-carboxamide Chemical compound C1=C2C=3CC(N(C)C)CCC=3OC2=CC=C1C(=O)NC1=CC=CN=C1 IDXQGNLNRBHUNL-UHFFFAOYSA-N 0.000 description 1
- LZQAISRJPXLERP-UHFFFAOYSA-N 8-(dimethylamino)-n-pyridin-4-yl-6,7,8,9-tetrahydrodibenzofuran-2-carboxamide Chemical compound C1=C2C=3CC(N(C)C)CCC=3OC2=CC=C1C(=O)NC1=CC=NC=C1 LZQAISRJPXLERP-UHFFFAOYSA-N 0.000 description 1
- GJTXHESFKJDOFH-UHFFFAOYSA-N 8-chloro-n,n-diethyl-1,2,3,4-tetrahydronaphthalen-2-amine;hydrochloride Chemical compound Cl.C1=CC(Cl)=C2CC(N(CC)CC)CCC2=C1 GJTXHESFKJDOFH-UHFFFAOYSA-N 0.000 description 1
- MEQZBIMXNYEWNV-UHFFFAOYSA-N 8-iodo-n,n-dipropyl-1,2,3,4-tetrahydrodibenzofuran-2-amine;hydrobromide Chemical compound Br.O1C2=CC=C(I)C=C2C2=C1CCC(N(CCC)CCC)C2 MEQZBIMXNYEWNV-UHFFFAOYSA-N 0.000 description 1
- OQSZSKPAYWNSRR-UHFFFAOYSA-N 8-nitro-1,2,3,4-tetrahydrodibenzofuran-2-amine Chemical compound O1C2=CC=C([N+]([O-])=O)C=C2C2=C1CCC(N)C2 OQSZSKPAYWNSRR-UHFFFAOYSA-N 0.000 description 1
- NQAVACZCGKSUCI-UHFFFAOYSA-N 9-chloro-n-ethyl-1h-cyclohepta[b][1]benzofuran-2-amine;sulfuric acid Chemical compound OS(O)(=O)=O.O1C2=CC=CC(Cl)=CC2=C2C1=CC=C(NCC)C2 NQAVACZCGKSUCI-UHFFFAOYSA-N 0.000 description 1
- YWXUEPRCBDSUFI-UHFFFAOYSA-N 9-iodo-n,n-dipropyl-1h-cyclohepta[b][1]benzofuran-2-amine;hydrobromide Chemical compound Br.O1C2=CC=CC(I)=CC2=C2C1=CC=C(N(CCC)CCC)C2 YWXUEPRCBDSUFI-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 208000000103 Anorexia Nervosa Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 description 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 description 1
- 206010003805 Autism Diseases 0.000 description 1
- 208000020706 Autistic disease Diseases 0.000 description 1
- 229910015900 BF3 Inorganic materials 0.000 description 1
- KHBQMWCZKVMBLN-UHFFFAOYSA-N Benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1 KHBQMWCZKVMBLN-UHFFFAOYSA-N 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- COXVTLYNGOIATD-HVMBLDELSA-N CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O Chemical group CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O COXVTLYNGOIATD-HVMBLDELSA-N 0.000 description 1
- DRSHXJFUUPIBHX-UHFFFAOYSA-N COc1ccc(cc1)N1N=CC2C=NC(Nc3cc(OC)c(OC)c(OCCCN4CCN(C)CC4)c3)=NC12 Chemical compound COc1ccc(cc1)N1N=CC2C=NC(Nc3cc(OC)c(OC)c(OCCCN4CCN(C)CC4)c3)=NC12 DRSHXJFUUPIBHX-UHFFFAOYSA-N 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-N Carbamic acid Chemical class NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 description 1
- LSGJZWMCZRFQFQ-UHFFFAOYSA-N ClC1=CC=C(C(=O)O)C=C1.N1=NC=C(C=C1)C(=O)N Chemical compound ClC1=CC=C(C(=O)O)C=C1.N1=NC=C(C=C1)C(=O)N LSGJZWMCZRFQFQ-UHFFFAOYSA-N 0.000 description 1
- 229940126062 Compound A Drugs 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- HTJDQJBWANPRPF-UHFFFAOYSA-N Cyclopropylamine Chemical compound NC1CC1 HTJDQJBWANPRPF-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- BFPYWIDHMRZLRN-SLHNCBLASA-N Ethinyl estradiol Chemical group OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SLHNCBLASA-N 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- 108091006027 G proteins Proteins 0.000 description 1
- 102000030782 GTP binding Human genes 0.000 description 1
- 108091000058 GTP-Binding Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-M Glycolate Chemical compound OCC([O-])=O AEMRFAOFKBGASW-UHFFFAOYSA-M 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 1
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
- 240000001812 Hyssopus officinalis Species 0.000 description 1
- 235000010650 Hyssopus officinalis Nutrition 0.000 description 1
- 235000003332 Ilex aquifolium Nutrition 0.000 description 1
- 241000209027 Ilex aquifolium Species 0.000 description 1
- 229930194542 Keto Natural products 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 239000002841 Lewis acid Substances 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000026139 Memory disease Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 1
- RLJFTICUTYVZDG-UHFFFAOYSA-N Methiothepine Chemical compound C12=CC(SC)=CC=C2SC2=CC=CC=C2CC1N1CCN(C)CC1 RLJFTICUTYVZDG-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 208000007920 Neurogenic Inflammation Diseases 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- ZJQRLCACHKKYOT-UHFFFAOYSA-N OC(=O)C(Cl)Cl.NC(=O)c1nccc2ccccc12 Chemical compound OC(=O)C(Cl)Cl.NC(=O)c1nccc2ccccc12 ZJQRLCACHKKYOT-UHFFFAOYSA-N 0.000 description 1
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 description 1
- 241000233855 Orchidaceae Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 description 1
- 229920002873 Polyethylenimine Polymers 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 208000008348 Post-Concussion Syndrome Diseases 0.000 description 1
- 206010036618 Premenstrual syndrome Diseases 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 239000007868 Raney catalyst Substances 0.000 description 1
- NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 1
- 229910000564 Raney nickel Inorganic materials 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- 241000220010 Rhode Species 0.000 description 1
- 241000270295 Serpentes Species 0.000 description 1
- 206010041250 Social phobia Diseases 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical compound OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 1
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 1
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
- 206010043903 Tobacco abuse Diseases 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 229910052770 Uranium Inorganic materials 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical class NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- ZZXDRXVIRVJQBT-UHFFFAOYSA-M Xylenesulfonate Chemical compound CC1=CC=CC(S([O-])(=O)=O)=C1C ZZXDRXVIRVJQBT-UHFFFAOYSA-M 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- KPCZJLGGXRGYIE-UHFFFAOYSA-N [C]1=CC=CN=C1 Chemical group [C]1=CC=CN=C1 KPCZJLGGXRGYIE-UHFFFAOYSA-N 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- IPBVNPXQWQGGJP-UHFFFAOYSA-N acetic acid phenyl ester Natural products CC(=O)OC1=CC=CC=C1 IPBVNPXQWQGGJP-UHFFFAOYSA-N 0.000 description 1
- RWCWDUQJFSEZBB-UHFFFAOYSA-N acetic acid;n-[2-(dimethylamino)-1h-cyclohepta[b][1]benzofuran-9-yl]cyclobutanecarboxamide Chemical compound CC(O)=O.C=1C2=C3CC(N(C)C)=CC=C3OC2=CC=CC=1NC(=O)C1CCC1 RWCWDUQJFSEZBB-UHFFFAOYSA-N 0.000 description 1
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 1
- 239000012346 acetyl chloride Substances 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- YTIVTFGABIZHHX-UHFFFAOYSA-L acetylenedicarboxylate(2-) Chemical compound [O-]C(=O)C#CC([O-])=O YTIVTFGABIZHHX-UHFFFAOYSA-L 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 102000030621 adenylate cyclase Human genes 0.000 description 1
- 108060000200 adenylate cyclase Proteins 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 150000001350 alkyl halides Chemical class 0.000 description 1
- 125000004414 alkyl thio group Chemical group 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- UKFWSNCTAHXBQN-UHFFFAOYSA-N ammonium iodide Chemical compound [NH4+].[I-] UKFWSNCTAHXBQN-UHFFFAOYSA-N 0.000 description 1
- 229940107816 ammonium iodide Drugs 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 239000000010 aprotic solvent Substances 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 description 1
- 210000003050 axon Anatomy 0.000 description 1
- CSKNSYBAZOQPLR-UHFFFAOYSA-N benzenesulfonyl chloride Chemical compound ClS(=O)(=O)C1=CC=CC=C1 CSKNSYBAZOQPLR-UHFFFAOYSA-N 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000003124 biologic agent Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 239000001045 blue dye Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- KZMGYPLQYOPHEL-UHFFFAOYSA-N boron trifluoride etherate Substances FB(F)F.CCOCC KZMGYPLQYOPHEL-UHFFFAOYSA-N 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 150000001649 bromium compounds Chemical class 0.000 description 1
- ODWXUNBKCRECNW-UHFFFAOYSA-M bromocopper(1+) Chemical compound Br[Cu+] ODWXUNBKCRECNW-UHFFFAOYSA-M 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000003491 cAMP production Effects 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 229960003340 calcium silicate Drugs 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 1
- 150000003857 carboxamides Chemical class 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 238000004517 catalytic hydrocracking Methods 0.000 description 1
- 238000010531 catalytic reduction reaction Methods 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 210000004289 cerebral ventricle Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- KVSASDOGYIBWTA-UHFFFAOYSA-N chloro benzoate Chemical compound ClOC(=O)C1=CC=CC=C1 KVSASDOGYIBWTA-UHFFFAOYSA-N 0.000 description 1
- MVPPADPHJFYWMZ-UHFFFAOYSA-N chlorobenzene Chemical compound ClC1=CC=CC=C1 MVPPADPHJFYWMZ-UHFFFAOYSA-N 0.000 description 1
- 239000002026 chloroform extract Substances 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- ORTQZVOHEJQUHG-UHFFFAOYSA-L copper(II) chloride Chemical compound Cl[Cu]Cl ORTQZVOHEJQUHG-UHFFFAOYSA-L 0.000 description 1
- DOBRDRYODQBAMW-UHFFFAOYSA-N copper(i) cyanide Chemical compound [Cu+].N#[C-] DOBRDRYODQBAMW-UHFFFAOYSA-N 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 239000002178 crystalline material Substances 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- PNZXMIKHJXIPEK-UHFFFAOYSA-N cyclohexanecarboxamide Chemical compound NC(=O)C1CCCCC1 PNZXMIKHJXIPEK-UHFFFAOYSA-N 0.000 description 1
- HPXRVTGHNJAIIH-UHFFFAOYSA-N cyclohexanol Chemical compound OC1CCCCC1 HPXRVTGHNJAIIH-UHFFFAOYSA-N 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- AIMMVWOEOZMVMS-UHFFFAOYSA-N cyclopropanecarboxamide Chemical compound NC(=O)C1CC1 AIMMVWOEOZMVMS-UHFFFAOYSA-N 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 238000006114 decarboxylation reaction Methods 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- RCDMUNHSQCVVBJ-UHFFFAOYSA-N dibenzofuran-1-amine Chemical compound O1C2=CC=CC=C2C2=C1C=CC=C2N RCDMUNHSQCVVBJ-UHFFFAOYSA-N 0.000 description 1
- FFYZMBQLAYDJIG-UHFFFAOYSA-N dibenzofuran-2-amine Chemical compound C1=CC=C2C3=CC(N)=CC=C3OC2=C1 FFYZMBQLAYDJIG-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-M dihydrogenphosphate Chemical compound OP(O)([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-M 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229960003133 ergot alkaloid Drugs 0.000 description 1
- ZCRZCMUDOWDGOB-UHFFFAOYSA-N ethanesulfonimidic acid Chemical compound CCS(N)(=O)=O ZCRZCMUDOWDGOB-UHFFFAOYSA-N 0.000 description 1
- NLFBCYMMUAKCPC-KQQUZDAGSA-N ethyl (e)-3-[3-amino-2-cyano-1-[(e)-3-ethoxy-3-oxoprop-1-enyl]sulfanyl-3-oxoprop-1-enyl]sulfanylprop-2-enoate Chemical compound CCOC(=O)\C=C\SC(=C(C#N)C(N)=O)S\C=C\C(=O)OCC NLFBCYMMUAKCPC-KQQUZDAGSA-N 0.000 description 1
- QPMJENKZJUFOON-PLNGDYQASA-N ethyl (z)-3-chloro-2-cyano-4,4,4-trifluorobut-2-enoate Chemical compound CCOC(=O)C(\C#N)=C(/Cl)C(F)(F)F QPMJENKZJUFOON-PLNGDYQASA-N 0.000 description 1
- UMPRJGKLMUDRHL-UHFFFAOYSA-N ethyl 4-fluorobenzoate Chemical compound CCOC(=O)C1=CC=C(F)C=C1 UMPRJGKLMUDRHL-UHFFFAOYSA-N 0.000 description 1
- GPZBLLFIAMLNIB-UHFFFAOYSA-N ethyl 8-(dimethylamino)-6,7,8,9-tetrahydrodibenzofuran-2-carboxylate Chemical compound C1CC(N(C)C)CC2=C1OC1=CC=C(C(=O)OCC)C=C12 GPZBLLFIAMLNIB-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 229960004979 fampridine Drugs 0.000 description 1
- 210000003191 femoral vein Anatomy 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- ZPYNUFUFMQTZMO-UHFFFAOYSA-N formic acid;1h-pyrazole-5-carboxamide Chemical compound OC=O.NC(=O)C1=CC=NN1 ZPYNUFUFMQTZMO-UHFFFAOYSA-N 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 238000002825 functional assay Methods 0.000 description 1
- UTVVREMVDJTZAC-UHFFFAOYSA-N furan-2-amine Chemical compound NC1=CC=CO1 UTVVREMVDJTZAC-UHFFFAOYSA-N 0.000 description 1
- TVFIYRKPCACCNL-UHFFFAOYSA-N furan-2-carboxamide Chemical compound NC(=O)C1=CC=CO1 TVFIYRKPCACCNL-UHFFFAOYSA-N 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 229940014259 gelatin Drugs 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 208000024963 hair loss Diseases 0.000 description 1
- 230000003676 hair loss Effects 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 1
- KKLGDUSGQMHBPB-UHFFFAOYSA-N hex-2-ynedioic acid Chemical compound OC(=O)CCC#CC(O)=O KKLGDUSGQMHBPB-UHFFFAOYSA-N 0.000 description 1
- BQIFLVBDWKFBNJ-UHFFFAOYSA-N hexanamide;phosphoric acid Chemical compound OP(O)(O)=O.CCCCCC(N)=O BQIFLVBDWKFBNJ-UHFFFAOYSA-N 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-M hexanoate Chemical compound CCCCCC([O-])=O FUZZWVXGSFPDMH-UHFFFAOYSA-M 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000008240 homogeneous mixture Substances 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 1
- 150000004678 hydrides Chemical class 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- DCPMPXBYPZGNDC-UHFFFAOYSA-N hydron;methanediimine;chloride Chemical compound Cl.N=C=N DCPMPXBYPZGNDC-UHFFFAOYSA-N 0.000 description 1
- BNTRVUUJBGBGLZ-UHFFFAOYSA-N hydron;pyridine-4-carbonyl chloride;chloride Chemical compound Cl.ClC(=O)C1=CC=NC=C1 BNTRVUUJBGBGLZ-UHFFFAOYSA-N 0.000 description 1
- 239000000819 hypertonic solution Substances 0.000 description 1
- 229940021223 hypertonic solution Drugs 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 210000004283 incisor Anatomy 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 150000004694 iodide salts Chemical class 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- HVTICUPFWKNHNG-UHFFFAOYSA-N iodoethane Chemical compound CCI HVTICUPFWKNHNG-UHFFFAOYSA-N 0.000 description 1
- 230000003447 ipsilateral effect Effects 0.000 description 1
- KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 125000000468 ketone group Chemical group 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 150000007517 lewis acids Chemical class 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 239000011344 liquid material Substances 0.000 description 1
- 239000012280 lithium aluminium hydride Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 230000029849 luteinization Effects 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000005291 magnetic effect Effects 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 150000002690 malonic acid derivatives Chemical class 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000006984 memory degeneration Effects 0.000 description 1
- 208000023060 memory loss Diseases 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 125000005341 metaphosphate group Chemical group 0.000 description 1
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Natural products C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 1
- IZDROVVXIHRYMH-UHFFFAOYSA-N methanesulfonic anhydride Chemical group CS(=O)(=O)OS(C)(=O)=O IZDROVVXIHRYMH-UHFFFAOYSA-N 0.000 description 1
- HNQIVZYLYMDVSB-UHFFFAOYSA-N methanesulfonimidic acid Chemical compound CS(N)(=O)=O HNQIVZYLYMDVSB-UHFFFAOYSA-N 0.000 description 1
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 1
- 238000006140 methanolysis reaction Methods 0.000 description 1
- IZYBEMGNIUSSAX-UHFFFAOYSA-N methyl benzenecarboperoxoate Chemical compound COOC(=O)C1=CC=CC=C1 IZYBEMGNIUSSAX-UHFFFAOYSA-N 0.000 description 1
- 229940095102 methyl benzoate Drugs 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 210000002464 muscle smooth vascular Anatomy 0.000 description 1
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 description 1
- ZJSUZLHVZVOIAB-UHFFFAOYSA-N n,n-diethyl-8-fluoro-1,2,3,4-tetrahydrodibenzofuran-2-amine Chemical compound O1C2=CC=C(F)C=C2C2=C1CCC(N(CC)CC)C2 ZJSUZLHVZVOIAB-UHFFFAOYSA-N 0.000 description 1
- XHYMAIMHWGQJDM-UHFFFAOYSA-N n,n-diethyl-9-fluoro-1h-cyclohepta[b][1]benzofuran-2-amine Chemical compound O1C2=CC=CC(F)=CC2=C2C1=CC=C(N(CC)CC)C2 XHYMAIMHWGQJDM-UHFFFAOYSA-N 0.000 description 1
- ZWBAAVILJVUPFQ-UHFFFAOYSA-N n,n-dimethyl-8-nitro-1,2,3,4-tetrahydrodibenzofuran-2-amine Chemical compound O1C2=CC=C([N+]([O-])=O)C=C2C2=C1CCC(N(C)C)C2 ZWBAAVILJVUPFQ-UHFFFAOYSA-N 0.000 description 1
- ZUHZZVMEUAUWHY-UHFFFAOYSA-N n,n-dimethylpropan-1-amine Chemical compound CCCN(C)C ZUHZZVMEUAUWHY-UHFFFAOYSA-N 0.000 description 1
- PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 1
- OBVKHIXHBNQFGJ-UHFFFAOYSA-N n-[2-(dibutylamino)-1h-cyclohepta[b][1]benzofuran-9-yl]-2-methylquinoline-6-carboxamide;methanesulfonic acid Chemical compound CS(O)(=O)=O.O1C2=CC=CC(NC(=O)C=3C=C4C=CC(C)=NC4=CC=3)=CC2=C2C1=CC=C(N(CCCC)CCCC)C2 OBVKHIXHBNQFGJ-UHFFFAOYSA-N 0.000 description 1
- CTKVOIZOIHRMBD-UHFFFAOYSA-N n-[2-(dimethylamino)-1h-cyclohepta[b][1]benzofuran-9-yl]-1,2-oxazole-3-carboxamide Chemical compound C=1C2=C3CC(N(C)C)=CC=C3OC2=CC=CC=1NC(=O)C=1C=CON=1 CTKVOIZOIHRMBD-UHFFFAOYSA-N 0.000 description 1
- KIJDGHVREVDQNW-UHFFFAOYSA-N n-[2-(dimethylamino)-1h-cyclohepta[b][1]benzofuran-9-yl]-1h-imidazole-2-carboxamide;propanedioic acid Chemical compound OC(=O)CC(O)=O.C=1C2=C3CC(N(C)C)=CC=C3OC2=CC=CC=1NC(=O)C1=NC=CN1 KIJDGHVREVDQNW-UHFFFAOYSA-N 0.000 description 1
- KOVKTLZKPDGRRN-UHFFFAOYSA-N n-[2-(dimethylamino)-1h-cyclohepta[b][1]benzofuran-9-yl]-1h-imidazole-5-carboxamide Chemical compound C=1C2=C3CC(N(C)C)=CC=C3OC2=CC=CC=1NC(=O)C1=CNC=N1 KOVKTLZKPDGRRN-UHFFFAOYSA-N 0.000 description 1
- CBPGAESYQULXRF-UHFFFAOYSA-N n-[2-(dimethylamino)-1h-cyclohepta[b][1]benzofuran-9-yl]-1h-indole-3-carboxamide Chemical compound O1C2=CC=CC(NC(=O)C=3C4=CC=CC=C4NC=3)=CC2=C2C1=CC=C(N(C)C)C2 CBPGAESYQULXRF-UHFFFAOYSA-N 0.000 description 1
- ODYRXTLSWNOVHF-UHFFFAOYSA-N n-[2-(dimethylamino)-1h-cyclohepta[b][1]benzofuran-9-yl]-1h-indole-7-carboxamide Chemical compound O1C2=CC=CC(NC(=O)C=3C=4NC=CC=4C=CC=3)=CC2=C2C1=CC=C(N(C)C)C2 ODYRXTLSWNOVHF-UHFFFAOYSA-N 0.000 description 1
- DAKCTJBGVMNGDG-UHFFFAOYSA-N n-[2-(dimethylamino)-1h-cyclohepta[b][1]benzofuran-9-yl]-1h-pyrazole-5-carboxamide;formic acid Chemical compound OC=O.C=1C2=C3CC(N(C)C)=CC=C3OC2=CC=CC=1NC(=O)C=1C=CNN=1 DAKCTJBGVMNGDG-UHFFFAOYSA-N 0.000 description 1
- PEWLTIAKVFRNAO-UHFFFAOYSA-N n-[2-(dimethylamino)-1h-cyclohepta[b][1]benzofuran-9-yl]-1h-pyrrole-2-carboxamide Chemical compound C=1C2=C3CC(N(C)C)=CC=C3OC2=CC=CC=1NC(=O)C1=CC=CN1 PEWLTIAKVFRNAO-UHFFFAOYSA-N 0.000 description 1
- YXODJDACXBOKDA-UHFFFAOYSA-N n-[2-(dimethylamino)-1h-cyclohepta[b][1]benzofuran-9-yl]-2-phenylacetamide Chemical compound C=1C2=C3CC(N(C)C)=CC=C3OC2=CC=CC=1NC(=O)CC1=CC=CC=C1 YXODJDACXBOKDA-UHFFFAOYSA-N 0.000 description 1
- ITZKHHGASZYFRF-UHFFFAOYSA-N n-[2-(dimethylamino)-1h-cyclohepta[b][1]benzofuran-9-yl]-2-propyl-1,3-oxazole-4-carboxamide Chemical compound O1C(CCC)=NC(C(=O)NC=2C=CC=C3OC4=CC=C(CC4=C3C=2)N(C)C)=C1 ITZKHHGASZYFRF-UHFFFAOYSA-N 0.000 description 1
- MPBSHBLCBCPTSS-UHFFFAOYSA-N n-[2-(dimethylamino)-1h-cyclohepta[b][1]benzofuran-9-yl]-4-methylbenzenesulfonamide Chemical compound C=1C2=C3CC(N(C)C)=CC=C3OC2=CC=CC=1NS(=O)(=O)C1=CC=C(C)C=C1 MPBSHBLCBCPTSS-UHFFFAOYSA-N 0.000 description 1
- AHYGDGPUCSTCQB-UHFFFAOYSA-N n-[2-(dimethylamino)-1h-cyclohepta[b][1]benzofuran-9-yl]acetamide Chemical compound O1C2=CC=CC(NC(C)=O)=CC2=C2C1=CC=C(N(C)C)C2 AHYGDGPUCSTCQB-UHFFFAOYSA-N 0.000 description 1
- JEPBKKZLZDHDIV-UHFFFAOYSA-N n-[2-(dimethylamino)-1h-cyclohepta[b][1]benzofuran-9-yl]benzamide Chemical compound C=1C2=C3CC(N(C)C)=CC=C3OC2=CC=CC=1NC(=O)C1=CC=CC=C1 JEPBKKZLZDHDIV-UHFFFAOYSA-N 0.000 description 1
- SUVAEVKELZQHOJ-UHFFFAOYSA-N n-[2-(dimethylamino)-1h-cyclohepta[b][1]benzofuran-9-yl]benzenesulfonamide Chemical compound C=1C2=C3CC(N(C)C)=CC=C3OC2=CC=CC=1NS(=O)(=O)C1=CC=CC=C1 SUVAEVKELZQHOJ-UHFFFAOYSA-N 0.000 description 1
- YVDKNKOGWCKBAU-UHFFFAOYSA-N n-[2-(dimethylamino)-1h-cyclohepta[b][1]benzofuran-9-yl]cyclohexanecarboxamide Chemical compound C=1C2=C3CC(N(C)C)=CC=C3OC2=CC=CC=1NC(=O)C1CCCCC1 YVDKNKOGWCKBAU-UHFFFAOYSA-N 0.000 description 1
- JIDBFPUZBJWTMT-UHFFFAOYSA-N n-[2-(dimethylamino)-1h-cyclohepta[b][1]benzofuran-9-yl]ethanesulfonamide Chemical compound O1C2=CC=CC(NS(=O)(=O)CC)=CC2=C2C1=CC=C(N(C)C)C2 JIDBFPUZBJWTMT-UHFFFAOYSA-N 0.000 description 1
- OMFBOOGHESQDJD-UHFFFAOYSA-N n-[2-(dimethylamino)-1h-cyclohepta[b][1]benzofuran-9-yl]hexanamide;phosphoric acid Chemical compound OP(O)(O)=O.O1C2=CC=CC(NC(=O)CCCCC)=CC2=C2C1=CC=C(N(C)C)C2 OMFBOOGHESQDJD-UHFFFAOYSA-N 0.000 description 1
- ZLTIHBCRPGXBEI-UHFFFAOYSA-N n-[2-(dimethylamino)-1h-cyclohepta[b][1]benzofuran-9-yl]isoquinoline-1-carboxamide;trifluoromethanesulfonic acid Chemical compound OS(=O)(=O)C(F)(F)F.O1C2=CC=CC(NC(=O)C=3C4=CC=CC=C4C=CN=3)=CC2=C2C1=CC=C(N(C)C)C2 ZLTIHBCRPGXBEI-UHFFFAOYSA-N 0.000 description 1
- WPHRMBKYKNUXQR-UHFFFAOYSA-N n-[2-(dimethylamino)-1h-cyclohepta[b][1]benzofuran-9-yl]isoquinoline-3-carboxamide;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.O1C2=CC=CC(NC(=O)C=3N=CC4=CC=CC=C4C=3)=CC2=C2C1=CC=C(N(C)C)C2 WPHRMBKYKNUXQR-UHFFFAOYSA-N 0.000 description 1
- ASKSNDBKAWJGQH-UHFFFAOYSA-N n-[2-(dimethylamino)-1h-cyclohepta[b][1]benzofuran-9-yl]isoquinoline-6-carboxamide;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.O1C2=CC=CC(NC(=O)C=3C=C4C=CN=CC4=CC=3)=CC2=C2C1=CC=C(N(C)C)C2 ASKSNDBKAWJGQH-UHFFFAOYSA-N 0.000 description 1
- WIQASJLNRZELHL-UHFFFAOYSA-N n-[2-(dimethylamino)-1h-cyclohepta[b][1]benzofuran-9-yl]methanesulfonamide Chemical compound O1C2=CC=CC(NS(C)(=O)=O)=CC2=C2C1=CC=C(N(C)C)C2 WIQASJLNRZELHL-UHFFFAOYSA-N 0.000 description 1
- QYGADQRFLDPUGZ-UHFFFAOYSA-N n-[2-(dimethylamino)-1h-cyclohepta[b][1]benzofuran-9-yl]prop-2-enamide Chemical compound O1C2=CC=CC(NC(=O)C=C)=CC2=C2C1=CC=C(N(C)C)C2 QYGADQRFLDPUGZ-UHFFFAOYSA-N 0.000 description 1
- IXVGFIOMTBXPBT-UHFFFAOYSA-N n-[2-(dimethylamino)-1h-cyclohepta[b][1]benzofuran-9-yl]propanamide Chemical compound O1C2=CC=CC(NC(=O)CC)=CC2=C2C1=CC=C(N(C)C)C2 IXVGFIOMTBXPBT-UHFFFAOYSA-N 0.000 description 1
- IDIQPECYLCLEMO-UHFFFAOYSA-N n-[2-(dimethylamino)-1h-cyclohepta[b][1]benzofuran-9-yl]pyridazine-3-carboxamide Chemical compound C=1C2=C3CC(N(C)C)=CC=C3OC2=CC=CC=1NC(=O)C1=CC=CN=N1 IDIQPECYLCLEMO-UHFFFAOYSA-N 0.000 description 1
- QVTHERYJMVHWTR-UHFFFAOYSA-N n-[2-(dimethylamino)-1h-cyclohepta[b][1]benzofuran-9-yl]pyrimidine-2-carboxamide Chemical compound C=1C2=C3CC(N(C)C)=CC=C3OC2=CC=CC=1NC(=O)C1=NC=CC=N1 QVTHERYJMVHWTR-UHFFFAOYSA-N 0.000 description 1
- DHIPIJYBJKMMGQ-UHFFFAOYSA-N n-[2-(dimethylamino)-1h-cyclohepta[b][1]benzofuran-9-yl]quinoline-4-carboxamide;4-methylbenzenesulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1.O1C2=CC=CC(NC(=O)C=3C4=CC=CC=C4N=CC=3)=CC2=C2C1=CC=C(N(C)C)C2 DHIPIJYBJKMMGQ-UHFFFAOYSA-N 0.000 description 1
- KTODIBHNDYQCJL-UHFFFAOYSA-N n-[2-[methyl(2-phenylethyl)amino]-1h-cyclohepta[b][1]benzofuran-9-yl]quinoline-2-carboxamide;phthalic acid Chemical compound OC(=O)C1=CC=CC=C1C(O)=O.C=1C=C2OC3=CC=CC(NC(=O)C=4N=C5C=CC=CC5=CC=4)=CC3=C2CC=1N(C)CCC1=CC=CC=C1 KTODIBHNDYQCJL-UHFFFAOYSA-N 0.000 description 1
- YBERQZHPNVXCSO-UHFFFAOYSA-N n-[8-(dimethylamino)-6,7,8,9-tetrahydrodibenzofuran-2-yl]acetamide Chemical compound O1C2=CC=C(NC(C)=O)C=C2C2=C1CCC(N(C)C)C2 YBERQZHPNVXCSO-UHFFFAOYSA-N 0.000 description 1
- LQEBIECEKXYJMR-UHFFFAOYSA-N n-[8-(dimethylamino)-6,7,8,9-tetrahydrodibenzofuran-2-yl]benzamide Chemical compound C1=C2C=3CC(N(C)C)CCC=3OC2=CC=C1NC(=O)C1=CC=CC=C1 LQEBIECEKXYJMR-UHFFFAOYSA-N 0.000 description 1
- QXIFGJMWPDISCG-UHFFFAOYSA-N n-[8-(dimethylamino)-6,7,8,9-tetrahydrodibenzofuran-2-yl]furan-3-carboxamide;hydrochloride Chemical compound Cl.C1=C2C=3CC(N(C)C)CCC=3OC2=CC=C1NC(=O)C=1C=COC=1 QXIFGJMWPDISCG-UHFFFAOYSA-N 0.000 description 1
- QWPGPIZVQPGWAW-UHFFFAOYSA-N n-[8-(dimethylamino)-6,7,8,9-tetrahydrodibenzofuran-2-yl]methanesulfonamide Chemical compound O1C2=CC=C(NS(C)(=O)=O)C=C2C2=C1CCC(N(C)C)C2 QWPGPIZVQPGWAW-UHFFFAOYSA-N 0.000 description 1
- NWOCVKKYACJSON-UHFFFAOYSA-N n-[8-(hexylamino)-6,7,8,9-tetrahydrodibenzofuran-2-yl]pyridazine-3-carboxamide Chemical compound C1=C2C=3CC(NCCCCCC)CCC=3OC2=CC=C1NC(=O)C1=CC=CN=N1 NWOCVKKYACJSON-UHFFFAOYSA-N 0.000 description 1
- TVYSZKOTAABFKC-UHFFFAOYSA-N n-[8-[methyl(2-phenylethyl)amino]-6,7,8,9-tetrahydrodibenzofuran-2-yl]quinoline-2-carboxamide;phthalic acid Chemical compound OC(=O)C1=CC=CC=C1C(O)=O.C1CC=2OC3=CC=C(NC(=O)C=4N=C5C=CC=CC5=CC=4)C=C3C=2CC1N(C)CCC1=CC=CC=C1 TVYSZKOTAABFKC-UHFFFAOYSA-N 0.000 description 1
- LPVSFTRPKULZHD-UHFFFAOYSA-N n-benzyl-8-bromo-n-methyl-1,2,3,4-tetrahydrodibenzofuran-2-amine Chemical compound C1CC=2OC3=CC=C(Br)C=C3C=2CC1N(C)CC1=CC=CC=C1 LPVSFTRPKULZHD-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- BMZBBDJCGMUPJI-UHFFFAOYSA-N n-cyclopropyl-8-(dimethylamino)-6,7,8,9-tetrahydrodibenzofuran-2-carboxamide Chemical compound C1=C2C=3CC(N(C)C)CCC=3OC2=CC=C1C(=O)NC1CC1 BMZBBDJCGMUPJI-UHFFFAOYSA-N 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- PVWOIHVRPOBWPI-UHFFFAOYSA-N n-propyl iodide Chemical compound CCCI PVWOIHVRPOBWPI-UHFFFAOYSA-N 0.000 description 1
- PSZYNBSKGUBXEH-UHFFFAOYSA-N naphthalene-1-sulfonic acid Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-N 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- 230000010807 negative regulation of binding Effects 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000001272 neurogenic effect Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 125000003261 o-tolyl group Chemical group [H]C1=C([H])C(*)=C(C([H])=C1[H])C([H])([H])[H] 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-M octanoate Chemical compound CCCCCCCC([O-])=O WWZKQHOCKIZLMA-UHFFFAOYSA-M 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 150000003891 oxalate salts Chemical class 0.000 description 1
- QRSQRUVGXCMBSB-UHFFFAOYSA-N oxalic acid;3-piperidin-4-yl-1h-indol-5-ol Chemical compound OC(=O)C(O)=O.C12=CC(O)=CC=C2NC=C1C1CCNCC1 QRSQRUVGXCMBSB-UHFFFAOYSA-N 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 125000000636 p-nitrophenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)[N+]([O-])=O 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 208000019906 panic disease Diseases 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 208000022821 personality disease Diseases 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- XAMUDJHXFNRLCY-UHFFFAOYSA-N phenthoate Chemical compound CCOC(=O)C(SP(=S)(OC)OC)C1=CC=CC=C1 XAMUDJHXFNRLCY-UHFFFAOYSA-N 0.000 description 1
- DYUMLJSJISTVPV-UHFFFAOYSA-N phenyl propanoate Chemical compound CCC(=O)OC1=CC=CC=C1 DYUMLJSJISTVPV-UHFFFAOYSA-N 0.000 description 1
- 229940049953 phenylacetate Drugs 0.000 description 1
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
- 229950009215 phenylbutanoic acid Drugs 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 1
- XKJCHHZQLQNZHY-UHFFFAOYSA-N phthalimide Chemical compound C1=CC=C2C(=O)NC(=O)C2=C1 XKJCHHZQLQNZHY-UHFFFAOYSA-N 0.000 description 1
- 125000005543 phthalimide group Chemical class 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 229920000137 polyphosphoric acid Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 206010036596 premature ejaculation Diseases 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- KCXFHTAICRTXLI-UHFFFAOYSA-N propane-1-sulfonic acid Chemical compound CCCS(O)(=O)=O KCXFHTAICRTXLI-UHFFFAOYSA-N 0.000 description 1
- 125000001325 propanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- QLNJFJADRCOGBJ-UHFFFAOYSA-N propionamide Chemical compound CCC(N)=O QLNJFJADRCOGBJ-UHFFFAOYSA-N 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 230000005588 protonation Effects 0.000 description 1
- 230000000541 pulsatile effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- ILVXOBCQQYKLDS-UHFFFAOYSA-N pyridine N-oxide Chemical compound [O-][N+]1=CC=CC=C1 ILVXOBCQQYKLDS-UHFFFAOYSA-N 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 238000005956 quaternization reaction Methods 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 238000006268 reductive amination reaction Methods 0.000 description 1
- 238000000611 regression analysis Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 210000004761 scalp Anatomy 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- CXMXRPHRNRROMY-UHFFFAOYSA-N sebacic acid Chemical class OC(=O)CCCCCCCCC(O)=O CXMXRPHRNRROMY-UHFFFAOYSA-N 0.000 description 1
- 239000012056 semi-solid material Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000000862 serotonergic effect Effects 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 235000009518 sodium iodide Nutrition 0.000 description 1
- KKCBUQHMOMHUOY-UHFFFAOYSA-N sodium oxide Chemical compound [O-2].[Na+].[Na+] KKCBUQHMOMHUOY-UHFFFAOYSA-N 0.000 description 1
- 229910001948 sodium oxide Inorganic materials 0.000 description 1
- 229910001495 sodium tetrafluoroborate Inorganic materials 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000037351 starvation Effects 0.000 description 1
- TYFQFVWCELRYAO-UHFFFAOYSA-N suberic acid Chemical class OC(=O)CCCCCCC(O)=O TYFQFVWCELRYAO-UHFFFAOYSA-N 0.000 description 1
- 150000003890 succinate salts Chemical class 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- NBNBICNWNFQDDD-UHFFFAOYSA-N sulfuryl dibromide Chemical compound BrS(Br)(=O)=O NBNBICNWNFQDDD-UHFFFAOYSA-N 0.000 description 1
- YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical compound ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- USITZSVDRWZIRW-UHFFFAOYSA-N tert-butyl 9-amino-8-(dimethylamino)-6,7,8,9-tetrahydrodibenzofuran-2-carboxylate Chemical compound CN(C1C(C2=C(OC3=C2C=C(C=C3)C(=O)OC(C)(C)C)CC1)N)C USITZSVDRWZIRW-UHFFFAOYSA-N 0.000 description 1
- BKDLGMUIXWPYGD-UHFFFAOYSA-N tert-butyllithium Chemical compound [Li]C(C)(C)C BKDLGMUIXWPYGD-UHFFFAOYSA-N 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- 229960000278 theophylline Drugs 0.000 description 1
- 239000010936 titanium Substances 0.000 description 1
- 229910052719 titanium Inorganic materials 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 230000037317 transdermal delivery Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- 210000000836 trigeminal nuclei Anatomy 0.000 description 1
- 238000009827 uniform distribution Methods 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- 230000002227 vasoactive effect Effects 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 239000011534 wash buffer Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
- 229940071104 xylenesulfonate Drugs 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/91—Dibenzofurans; Hydrogenated dibenzofurans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/93—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems condensed with a ring other than six-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.式I: [式中、 R1およびR2は独立して、水素、C1−C4アルキル、ベンジル、またはα−メ チル−4−ニトロベンジルであり; Xは、ニトロ、ハロ、−OH、−NH2、−CN、−NHC(O)R3、−C(O) R6、−NHSO2R7、または−SO2NHR10であり; R3は、C1−C6アルキル、C2−C6アルケニル、C3−C8シクロアルキル、 フェニル、置換されているフェニル、ナフチル、フェニル(C1−C4アルキレン) 、チエニルメチル、またはヘテロ環であり; R6は、ヒドロキシ、アミノ、C1−C6アルコキシ、ベンジルオキシ、フェノ キシ、または−NHR8であり; R7は、C1−C6アルキル、フェニル、またはハロもしくはC1−C4アルキル で一置換されているフェニルであり; R8は、C1−C6アルキル、C2−C6アルケニル、C3−C8シクロアルキル、 フェニル、置換されているフェニル、ナフチル、またはヘテロ環であり;そして R10は、C1−C6アルキル、フェニル、またはハロもしくはC1−C4アルキル で一置換されているフェニルであり; mは、1または2である] の化合物、およびその医薬的に許容され得る塩類。 2.mが1である、請求項1に記載の化合物。 3.Xが−NHC(O)R3である、請求項1に記載の化合物。 4.R3がフェニル、置換されているフェニル、またはヘテロ環よりなる群から 選択される、請求項3に記載の化合物。 5.Xが−C(O)R6である、請求項1に記載の化合物。 6.R6が−NHR8である、請求項5に記載の化合物。 7.哺乳動物において5−HT1F受容体の活性化を増大させる方法であって、該 活性化を必要とする哺乳動物に、請求項1に記載の化合物の有効量を投与するこ とを含んでなる方法。 8.哺乳動物がヒトである、請求項7に記載の方法。 9.適当な医薬品担体、希釈剤、または賦形剤と組み合わせて、式I: [式中、 R1およびR2は独立して、水素、C1−C4アルキル、ベンジル、またはα−メ チル-4−ニトロベンジルであり; Xは、ニトロ、ハロ、−OH、−NH2、−CN、−NHC(O)R3、−C(O) R6、−NHSO2R7、または−SO2NHR10であり; R3は、C1−C6アルキル、C2−C6アルケニル、C3−C8シクロアルキル、 フェニル、置換されているフェニル、ナフチル、フェニル(C1−C4アルキレン) 、チエニルメチル、またはヘテロ環であり; R6は、ヒドロキシ、アミノ、C1−C6アルコキシ、ベンジルオキシ、フェノ キシ、または−NHR8であり; R7は、C1−C6アルキル、フェニル、またはハロもしくはC1−C4アルキル で一置換されているフェニルであり; R8は、C1−C6アルキル、C2−C6アルケニル、C3−C8シクロアルキル、 フェニル、置換されているフェニル、ナフチル、またはヘテロ環であり;そして R10は、C1−C6アルキル、フェニル、またはハロもしくはC1−C4アルキル で一置換されているフェニルであり; mは、1または2である] の化合物、およびその医薬的に許容され得る塩類の有効量を含んでなる医薬品製 剤。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US2474596P | 1996-08-28 | 1996-08-28 | |
US60/024,745 | 1996-08-28 | ||
PCT/US1997/014938 WO1998008502A1 (en) | 1996-08-28 | 1997-08-25 | SUBSTITUTED 1,2,3,4-TETRAHYDRO-2-DIBENZOFURANAMINES AND 2-AMINOCYCLOHEPTA[b]BENZOFURANS |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2000516957A true JP2000516957A (ja) | 2000-12-19 |
JP2000516957A5 JP2000516957A5 (ja) | 2004-11-04 |
Family
ID=21822177
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP10511794A Ceased JP2000516957A (ja) | 1996-08-28 | 1997-08-25 | 置換されている1,2,3,4―テトラヒドロ―2―ジベンゾフランアミン類および2―アミノシクロヘプタ[b]ベンゾフラン類 |
Country Status (23)
Country | Link |
---|---|
EP (1) | EP0929299B1 (ja) |
JP (1) | JP2000516957A (ja) |
KR (1) | KR20000035942A (ja) |
CN (1) | CN1228695A (ja) |
AT (1) | ATE251457T1 (ja) |
AU (1) | AU741324B2 (ja) |
BR (1) | BR9711273A (ja) |
CA (1) | CA2264267A1 (ja) |
CZ (1) | CZ64499A3 (ja) |
DE (1) | DE69725459T2 (ja) |
DK (1) | DK0929299T3 (ja) |
EA (1) | EA001912B1 (ja) |
ES (1) | ES2208948T3 (ja) |
HU (1) | HUP9902901A3 (ja) |
IL (1) | IL128500A (ja) |
NO (1) | NO990849L (ja) |
NZ (1) | NZ334031A (ja) |
PL (1) | PL331882A1 (ja) |
PT (1) | PT929299E (ja) |
TR (1) | TR199900430T2 (ja) |
UA (1) | UA48245C2 (ja) |
WO (1) | WO1998008502A1 (ja) |
YU (1) | YU10499A (ja) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
UA52778C2 (uk) | 1997-10-10 | 2003-01-15 | Янссен Фармацевтика Н.В. | Галогенозаміщені тетрациклічні похідні тетрагідрофурану, спосіб їх отримання та композиція на їх основі |
TWI263497B (en) | 2002-03-29 | 2006-10-11 | Lilly Co Eli | Pyridinoylpiperidines as 5-HT1F agonists |
CN1777584A (zh) | 2003-04-18 | 2006-05-24 | 伊莱利利公司 | 作为5-ht1f激动剂的(哌啶氧基)苯基、(哌啶氧基)吡啶基、(哌啶硫基)苯基和(哌啶硫基)吡啶基化合物 |
UA82711C2 (en) | 2003-09-12 | 2008-05-12 | Эли Лилли Энд Компани | Substituted 2-carbonylamino-6-piperidinaminopyridines and substituted 1-carbonylamino-3-piperidinaminobenzenes as 5-ht1f agonists |
DE602004008338T2 (de) | 2003-12-17 | 2008-05-29 | Eli Lilly And Co., Indianapolis | Substituierte (4-aminocyclohexen-1-yl) phenyl and (4-aminocyclohexen-1-yl) pyridinyl verbindungen als 5-ht1f agonisten |
CN1318411C (zh) * | 2005-03-21 | 2007-05-30 | 中国海洋大学 | 氢化轮枝霉酮类化合物及其制备方法和用途 |
CA2795062A1 (en) | 2010-04-02 | 2011-10-06 | Colucid Pharmaceuticals, Inc. | Compositions and methods of synthesis of pyridinoylpiperidine 5-ht1f agonists |
CN102887880B (zh) * | 2012-08-20 | 2014-10-29 | 东南大学 | 二苯并呋喃衍生物及其制备方法与用途 |
TWI829107B (zh) | 2019-07-09 | 2024-01-11 | 美商美國禮來大藥廠 | 大規模製備2,4,6-三氟-n-[6-(1-甲基-哌啶-4-羰基)-吡啶-2-基]-苯甲醯胺半琥珀酸鹽的方法及中間體,以及2,4,6-三氟-n-[6-(1-甲基-哌啶-4-羰基)-吡啶-2-基]-苯甲醯胺醋酸鹽之製備 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4668690A (en) * | 1985-12-30 | 1987-05-26 | Hoechst Roussel Pharmaceuticals Inc. | 1,2,3,4,4a,9b-hexahydro-4a-aminoalkyldibenzofurans useful as analgesics, anticonvulsants or antidepressants |
US5698571A (en) * | 1994-10-05 | 1997-12-16 | Eli Lilly And Company | 5-HT1F mediated inhibition of neurogenic meningeal extravasation: a method for the treatment of migraine |
US5521196A (en) * | 1994-10-05 | 1996-05-28 | Eli Lilly And Company | 5-HT1F agonists for the treatment of migraine |
-
1997
- 1997-08-25 IL IL12850097A patent/IL128500A/xx not_active IP Right Cessation
- 1997-08-25 KR KR1019997001683A patent/KR20000035942A/ko not_active Application Discontinuation
- 1997-08-25 DE DE69725459T patent/DE69725459T2/de not_active Expired - Fee Related
- 1997-08-25 BR BR9711273A patent/BR9711273A/pt not_active IP Right Cessation
- 1997-08-25 AT AT97938585T patent/ATE251457T1/de not_active IP Right Cessation
- 1997-08-25 ES ES97938585T patent/ES2208948T3/es not_active Expired - Lifetime
- 1997-08-25 EA EA199900241A patent/EA001912B1/ru not_active IP Right Cessation
- 1997-08-25 CZ CZ99644A patent/CZ64499A3/cs unknown
- 1997-08-25 NZ NZ334031A patent/NZ334031A/xx unknown
- 1997-08-25 PT PT97938585T patent/PT929299E/pt unknown
- 1997-08-25 CN CN97197483A patent/CN1228695A/zh active Pending
- 1997-08-25 AU AU40880/97A patent/AU741324B2/en not_active Ceased
- 1997-08-25 PL PL97331882A patent/PL331882A1/xx unknown
- 1997-08-25 CA CA002264267A patent/CA2264267A1/en not_active Abandoned
- 1997-08-25 TR TR1999/00430T patent/TR199900430T2/xx unknown
- 1997-08-25 HU HU9902901A patent/HUP9902901A3/hu unknown
- 1997-08-25 UA UA99021147A patent/UA48245C2/uk unknown
- 1997-08-25 DK DK97938585T patent/DK0929299T3/da active
- 1997-08-25 JP JP10511794A patent/JP2000516957A/ja not_active Ceased
- 1997-08-25 EP EP97938585A patent/EP0929299B1/en not_active Expired - Lifetime
- 1997-08-25 WO PCT/US1997/014938 patent/WO1998008502A1/en not_active Application Discontinuation
- 1997-08-25 YU YU10499A patent/YU10499A/sh unknown
-
1999
- 1999-02-23 NO NO990849A patent/NO990849L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
EA199900241A1 (ru) | 1999-08-26 |
UA48245C2 (uk) | 2002-08-15 |
YU10499A (sh) | 2001-03-07 |
NO990849D0 (no) | 1999-02-23 |
TR199900430T2 (xx) | 1999-06-21 |
CN1228695A (zh) | 1999-09-15 |
IL128500A (en) | 2003-06-24 |
CZ64499A3 (cs) | 1999-05-12 |
AU741324B2 (en) | 2001-11-29 |
IL128500A0 (en) | 2000-01-31 |
ES2208948T3 (es) | 2004-06-16 |
WO1998008502A1 (en) | 1998-03-05 |
HUP9902901A3 (en) | 2002-01-28 |
EA001912B1 (ru) | 2001-10-22 |
NO990849L (no) | 1999-02-23 |
DE69725459T2 (de) | 2004-08-12 |
DE69725459D1 (de) | 2003-11-13 |
DK0929299T3 (da) | 2004-02-16 |
ATE251457T1 (de) | 2003-10-15 |
NZ334031A (en) | 2000-07-28 |
PT929299E (pt) | 2004-02-27 |
BR9711273A (pt) | 1999-08-17 |
PL331882A1 (en) | 1999-08-16 |
CA2264267A1 (en) | 1998-03-05 |
EP0929299A4 (en) | 2000-12-20 |
KR20000035942A (ko) | 2000-06-26 |
HUP9902901A2 (hu) | 2000-05-28 |
EP0929299B1 (en) | 2003-10-08 |
EP0929299A1 (en) | 1999-07-21 |
AU4088097A (en) | 1998-03-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5708187A (en) | 6-substituted-1,2,3,4-tetrahydro-9H-carbazoles and 7-substituted-10H-cyclohepta 7,6-B!indoles: New 5-HT1F agonists | |
US6126932A (en) | Polymer bound carbodiimide coupling reagent | |
US5792763A (en) | Serotonin 5-HT1F agonists | |
JP2002513387A (ja) | 選択的β▲下3▼アドレナリン作動性アゴニスト | |
JP2001503774A (ja) | 5―ht▲下1f▼アゴニスト | |
JPH09504287A (ja) | 新規な(r)−5−カルバモイル−8−フルオロ−3−n,n−ジ置換−アミノ−3,4−ジヒドロ−2h−1−ベンゾピラン | |
EP1798233A1 (en) | Pyrrolo[1,2-a]quinoxaline derivatives as Adenosine A3 receptor modulators and uses thereof | |
JP2001521529A (ja) | 置換へテロ芳香環5−ht▲下1f▼アゴニスト | |
JP3731827B2 (ja) | アミノメチルインダン、‐ベンゾフラン及び‐ベンゾチオフエン | |
AU729786B2 (en) | Carboxamides useful as 5-HT1F agonists | |
JP2000516957A (ja) | 置換されている1,2,3,4―テトラヒドロ―2―ジベンゾフランアミン類および2―アミノシクロヘプタ[b]ベンゾフラン類 | |
EP0749962B1 (en) | 6-substituted-1,2,3,4-tetrahydro-9H-carbazoles and 7-substituted-10H-cyclohepta(7,6-B)indoles | |
US5935992A (en) | Substituted 1,2,3,4-tetrahydro-2-dibenzofuranamines and 2-aminocyclohepta 6,!benzofurans | |
JP2002526547A (ja) | 医薬としての三環性δ3−ピペリジン類 | |
PL171013B1 (pl) | Sposób wytwarzania nowego 3-(N-izopropylo-N-n-propyloamino)-5-(N-izopropylo)karbamoilochromanu PL PL PL PL PL | |
JP2003519229A (ja) | 新規ヘテロアリール誘導体、その製造方法及びその使用方法 | |
WO2005100355A1 (ja) | 環状アミン化合物 | |
MXPA99001756A (en) | SUBSTITUTED 1,2,3,4-TETRAHYDRO-2-DIBENZOFURANAMINES AND 2-AMINOCYCLOHEPTA[b]BENZOFURANS | |
Fritz et al. | Serotonin 5-HT 1F agonists | |
JP2007516266A (ja) | 5−ht1fアゴニストとしての置換(4−アミノシクロヘキセン−1−イル)フェニルおよび(4−アミノシクロヘキセン−1−イル)ピリジニル化合物 | |
EP0994109A2 (en) | 1-(3-(1-Pyrrolidinyl)propyl)-3-ethylcarbodiimide and a solid phase coupling agent | |
CZ433099A3 (cs) | Karboxamidy jako 5-HT1F agonisté a farmaceutický prostředek s jejich obsahem |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20031209 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20031209 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20070821 |
|
A313 | Final decision of rejection without a dissenting response from the applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A313 Effective date: 20080109 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20080226 |